Bacteria-derived chimeric toxins as potential anticancer agents.

Saeed Khoshnood, Hadis Fathizadeh, Foroogh Neamati, Babak Negahdari, Piyush Baindara, Mohd Azmuddin Abdullah, Mohammad Hossein Haddadi
Author Information
  1. Saeed Khoshnood: Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran.
  2. Hadis Fathizadeh: Student Research Committee, Sirjan School of Medical Sciences, Sirjan, Iran.
  3. Foroogh Neamati: Department of Microbiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  4. Babak Negahdari: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  5. Piyush Baindara: Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, United States.
  6. Mohd Azmuddin Abdullah: Department of Toxicology, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam Campus, Kepala Batas, Pulau Pinang, Malaysia.
  7. Mohammad Hossein Haddadi: Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran.

Abstract

Cancer is one of the major causes of death globally, requiring everlasting efforts to develop novel, specific, effective, and safe treatment strategies. Despite advances in recent years, chemotherapy, as the primary treatment for cancer, still faces limitations such as the lack of specificity, drug resistance, and treatment failure. Bacterial toxins have great potential to be used as anticancer agents and can boost the effectiveness of cancer chemotherapeutics. Bacterial toxins exert anticancer effects by affecting the cell cycle and apoptotic pathways and regulating tumorigenesis. Chimeric toxins, which are recombinant derivatives of bacterial toxins, have been developed to address the low specificity of their conventional peers. Through their targeting moieties, chimeric toxins can specifically and effectively detect and kill cancer cells. This review takes a comprehensive look at the anticancer properties of bacteria-derived toxins and discusses their potential applications as therapeutic options for integrative cancer treatment.

Keywords

References

  1. Am J Pathol. 2004 May;164(5):1627-33 [PMID: 15111309]
  2. J Basic Clin Med. 2013;2(2):1-6 [PMID: 25309827]
  3. Appl Microbiol Biotechnol. 2006 Mar;70(1):78-84 [PMID: 16080007]
  4. Protein Pept Lett. 2021;28(2):122-130 [PMID: 32729411]
  5. Mol Cancer Ther. 2014 Aug;13(8):2040-9 [PMID: 24928849]
  6. Nature. 2005 Aug 18;436(7053):979-84 [PMID: 16107839]
  7. Clin Transl Immunology. 2019 Aug 05;8(8):e1073 [PMID: 31406574]
  8. Tumour Biol. 2017 Feb;39(2):1010428317692226 [PMID: 28218037]
  9. Gastroenterology. 2001 Sep;121(3):678-84 [PMID: 11522752]
  10. Clin Cancer Res. 2016 Mar 1;22(5):1055-8 [PMID: 26463707]
  11. Eur J Pharm Sci. 2021 Jun 1;161:105784 [PMID: 33677023]
  12. Monoclon Antib Immunodiagn Immunother. 2021 Jun;40(3):113-117 [PMID: 34076502]
  13. Drugs. 2019 Apr;79(5):579-583 [PMID: 30859413]
  14. Toxins (Basel). 2021 Sep 28;13(10): [PMID: 34678982]
  15. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 [PMID: 11724950]
  16. Iran J Cancer Prev. 2014 Summer;7(3):152-64 [PMID: 25250167]
  17. Cancer Res. 2005 Nov 1;65(21):9603-6 [PMID: 16266975]
  18. Toxins (Basel). 2020 Oct 15;12(10): [PMID: 33076544]
  19. ACS Chem Biol. 2018 Nov 16;13(11):3153-3160 [PMID: 30278129]
  20. Int J Mol Sci. 2020 Aug 31;21(17): [PMID: 32878291]
  21. Int Immunopharmacol. 2021 Jul;96:107759 [PMID: 34162138]
  22. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9485-8 [PMID: 2594781]
  23. CNS Oncol. 2019 Nov 1;8(3):CNS38 [PMID: 31747788]
  24. Front Microbiol. 2019 Oct 18;10:2340 [PMID: 31681205]
  25. J Exp Med. 1994 Jul 1;180(1):75-82 [PMID: 7516418]
  26. Toxins (Basel). 2019 Jan 05;11(1): [PMID: 30621280]
  27. Front Microbiol. 2019 Jun 05;10:1257 [PMID: 31231341]
  28. Blood Cancer J. 2018 Mar 20;8(3):33 [PMID: 29559616]
  29. Genes Dev. 2016 Jan 1;30(1):34-51 [PMID: 26701265]
  30. Semin Cancer Biol. 2021 Jul 13;: [PMID: 34271147]
  31. Biomedicines. 2019 Jan 05;7(1): [PMID: 30621282]
  32. J Steroid Biochem Mol Biol. 2020 Jun;200:105651 [PMID: 32147458]
  33. Int J Pharm. 2021 Jan 5;592:120037 [PMID: 33161038]
  34. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  35. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1622-1630 [PMID: 33629332]
  36. Biologics. 2008 Dec;2(4):717-24 [PMID: 19707452]
  37. Mol Cancer Ther. 2013 Jan;12(1):48-57 [PMID: 23136186]
  38. J Cell Biol. 1997 Mar 24;136(6):1239-47 [PMID: 9087440]
  39. Bioconjug Chem. 1992 Jan-Feb;3(1):63-8 [PMID: 1616951]
  40. Protein Expr Purif. 2022 Mar;191:106012 [PMID: 34767950]
  41. Anticancer Res. 2021 Jul;41(7):3471-3480 [PMID: 34230142]
  42. J Biol Chem. 1989 Aug 25;264(24):14256-61 [PMID: 2503515]
  43. Mol Oncol. 2015 Aug;9(7):1458-70 [PMID: 25958791]
  44. Chem Commun (Camb). 2017 Jan 3;53(3):573-576 [PMID: 27975087]
  45. Colloids Surf B Biointerfaces. 2021 Dec;208:112040 [PMID: 34425532]
  46. Eur J Pharm Biopharm. 2010 Jun;75(2):213-7 [PMID: 20226859]
  47. PLoS One. 2021 Jan 7;16(1):e0245024 [PMID: 33411835]
  48. Crit Rev Oncol Hematol. 2021 Jan;157:103161 [PMID: 33264716]
  49. CA Cancer J Clin. 2019 Sep;69(5):363-385 [PMID: 31184787]
  50. Eur J Pharmacol. 2021 May 15;899:174057 [PMID: 33753109]
  51. Toxicon. 2009 Dec 15;54(8):1206-14 [PMID: 19268683]
  52. Curr Cancer Drug Targets. 2002 Mar;2(1):19-36 [PMID: 12188918]
  53. Plant Mol Biol. 2018 May;97(1-2):103-112 [PMID: 29633168]
  54. Clin Cancer Res. 2005 May 15;11(10):3879-88 [PMID: 15897589]
  55. Expert Opin Investig Drugs. 2007 Feb;16(2):209-18 [PMID: 17243940]
  56. Biomolecules. 2020 Jun 30;10(7): [PMID: 32630017]
  57. J Pharm Sci. 2020 Jan;109(1):104-115 [PMID: 31669121]
  58. J Clin Oncol. 2000 Apr;18(8):1622-36 [PMID: 10764422]
  59. Int J Pharm. 2021 Oct 25;608:121081 [PMID: 34506924]
  60. Toxins (Basel). 2021 Oct 11;13(10): [PMID: 34679012]
  61. Leuk Res. 2005 Mar;29(3):331-41 [PMID: 15661270]
  62. Signal Transduct Target Ther. 2020 Mar 6;5(1):15 [PMID: 32296035]
  63. Cancer Immunol Immunother. 2010 May;59(5):737-46 [PMID: 20091030]
  64. Front Cell Dev Biol. 2021 May 24;9:677867 [PMID: 34109181]
  65. Toxicol In Vitro. 2022 Sep;83:105417 [PMID: 35718257]
  66. Appl Microbiol Biotechnol. 2018 Dec;102(24):10393-10408 [PMID: 30338356]
  67. J Biol Chem. 1995 Jul 14;270(28):16775-80 [PMID: 7622490]
  68. Science. 1987 Oct 23;238(4826):536-9 [PMID: 3498987]
  69. Nat Rev Cancer. 2006 Jul;6(7):559-65 [PMID: 16794638]
  70. BMC Cancer. 2011 Feb 08;11:61 [PMID: 21303546]
  71. Protein Expr Purif. 2000 Jul;19(2):304-11 [PMID: 10873546]
  72. Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):16938-16948 [PMID: 32616570]
  73. Cancer Invest. 2019;37(10):546-557 [PMID: 31597492]
  74. Mol Ther. 2021 Mar 3;29(3):1258-1278 [PMID: 33068778]
  75. J Immunol. 2007 Oct 1;179(7):4919-28 [PMID: 17878392]
  76. Biochemistry (Mosc). 2018 Mar;83(3):215-232 [PMID: 29625542]
  77. Sci Rep. 2017 Apr 19;7:46541 [PMID: 28422156]
  78. Cancer Immunol Immunother. 2022 Feb;71(2):353-363 [PMID: 34165607]
  79. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 May;21(3):269-72 [PMID: 15862136]
  80. Int J Mol Sci. 2021 Nov 30;22(23): [PMID: 34884780]
  81. Clin Lymphoma. 2002 Mar;2(4):222-8 [PMID: 11970761]
  82. Clin Cancer Res. 2011 Oct 15;17(20):6398-405 [PMID: 22003067]
  83. Life Sci. 2019 Oct 15;235:116839 [PMID: 31499068]
  84. Mol Cancer Ther. 2018 Jul;17(7):1486-1493 [PMID: 29695631]
  85. Biotechnol Bioeng. 2019 Sep;116(9):2236-2249 [PMID: 31140580]
  86. J Biol Chem. 1990 Jul 15;265(20):11885-9 [PMID: 2195027]
  87. Pharmacol Res. 2022 Aug;182:106282 [PMID: 35662630]
  88. J Immunother. 2009 Oct;32(8):817-25 [PMID: 19752752]
  89. PLoS One. 2011;6(9):e24012 [PMID: 21915275]
  90. Cancer Immunol Immunother. 2022 Jan;71(1):153-164 [PMID: 34043024]
  91. J Exp Med. 1988 Feb 1;167(2):612-22 [PMID: 3126255]
  92. Toxins (Basel). 2022 Jan 17;14(1): [PMID: 35051040]
  93. J Microbiol. 2021 Feb;59(2):113-123 [PMID: 33527313]
  94. J Med Microbiol. 2015 Feb;64(Pt 2):164-73 [PMID: 25627204]
  95. Biotechnol Adv. 2021 Mar-Apr;47:107683 [PMID: 33373687]
  96. Iran J Pharm Res. 2019 Spring;18(2):735-744 [PMID: 31531057]
  97. Toxicon. 2021 Jul 15;197:126-135 [PMID: 33901549]
  98. Front Oncol. 2020 Aug 06;10:1303 [PMID: 32850408]

Word Cloud

Created with Highcharts 10.0.0toxinsanticancertreatmentcancerchimericpotentialspecificityBacterialagentscanbacterialbacteria-derivedtoxinCanceronemajorcausesdeathgloballyrequiringeverlastingeffortsdevelopnovelspecificeffectivesafestrategiesDespiteadvancesrecentyearschemotherapyprimarystillfaceslimitationslackdrugresistancefailuregreatusedboosteffectivenesschemotherapeuticsexerteffectsaffectingcellcycleapoptoticpathwaysregulatingtumorigenesisChimericrecombinantderivativesdevelopedaddresslowconventionalpeerstargetingmoietiesspecificallyeffectivelydetectkillcellsreviewtakescomprehensivelookpropertiesdiscussesapplicationstherapeuticoptionsintegrativeBacteria-derivedaffibodyexotoxinimmunotoxinligand-basedimmunotoxins

Similar Articles

Cited By